DRI Capital is a global leader in healthcare investing. Toronto-based DRI Capital was established in 1992 and pioneered royalty monetization as a commonly accepted option for owners of intellectual property. In March 2010, Drug Royalty II achieved an oversubscribed final close with over $701 million of capital commitments. Drug Royalty II seeks to acquire shares in the royalties of drug sales from pharmaceutical and biotechnology companies, research institutions, universities and inventors.